Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

Audio By Carbonatix

SAN DIEGO--(BUSINESS WIRE)--Aug 25, 2025--

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that management will participate in the following upcoming investor conferences in September:

2025 Cantor Global Healthcare Conference
Investor Meetings: Wednesday, September 3, 2025
Location: New York, NY

2025 BofA Healthcare Trailblazers Private Company Conference
Investor Meetings: Wednesday, September 17, 2025
Location: Boston, MA

TD Cowen 5 th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Panel Discussion: Thursday, September 18, 2025
Location: Virtual

About Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by elunetirom (ABX-002), a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250825914686/en/

CONTACT: Investors:

Alex Straus

THRUST Strategic Communications

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS CALIFORNIA NEW YORK

INDUSTRY KEYWORD: BIOTECHNOLOGY NEUROLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL

SOURCE: Autobahn Therapeutics

Copyright Business Wire 2025.

PUB: 08/25/2025 08:00 AM/DISC: 08/25/2025 08:00 AM

http://www.businesswire.com/news/home/20250825914686/en